Relieving Burden of Hypophosphatasia in Adults With Functional Impairment Due to Chronic Disease

Summary

The study will evaluate safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of 2 different doses (approved dose and lower dose) of asfotase alfa in adult participants with pediatric-onset hypophosphatasia (HPP).

Timeline

Start

2020-04

Primary completion

2022-08

Completion

2022-08

Outcome

Outcome not reported

Stopped (Business): “R\&D portfolio review and in light of the global impact of the COVID-19 pandemic”

Drugs

Indications